
Bumecard2 mg/4 ml
Incepta Pharmaceuticals Ltd.
Bumetanide is a loop diuretic indicated for the treatment of edema (fluid retention) associated with several established medical conditions.
Bumetanide is a loop diuretic indicated for the treatment of edema (fluid retention) associated with several established medical conditions. Its use is classified below by the strength of supporting evidence.
Bumetanide has been studied off-label in specialised settings such as neonatal seizure management and certain neurological/psychiatric research contexts; these uses are investigational, not part of standard approved labeling, and should only be undertaken under specialist supervision.
Dosage of Bumetanide must be individualized according to the patient's condition and response. The following are general adult starting ranges; treatment should be titrated by a physician.
| Indication | Adult Dose | Notes |
|---|---|---|
| Edema (heart failure, hepatic or renal disease) — oral | 0.5 mg to 2 mg once daily; may repeat at 4–5 hour intervals if needed, to a usual maximum of 10 mg/day | Give on an intermittent schedule (e.g., alternate days or 2–4 days on/off) where possible to reduce electrolyte disturbance. |
| Edema requiring rapid diuresis (e.g., acute pulmonary edema) — IV/IM | 0.5 mg to 1 mg given slowly by IV injection over 1–2 minutes, may repeat at 2–3 hour intervals; usual maximum 10 mg/day | For hospital use when oral therapy is impractical or a rapid effect is required. |
| Pediatric use | Safety and efficacy not formally established (see Use in Special Populations) | Use only under specialist supervision if considered necessary. |
Higher doses may be required to achieve adequate diuresis in renal impairment; dosing should be individualized and increased cautiously under close monitoring.
In hepatic cirrhosis with ascites, therapy should generally be initiated in hospital with careful monitoring of fluid and electrolyte status, as excessive diuresis can precipitate hepatic encephalopathy.
Side effects of Bumetanide are generally related to its diuretic effect and fluid/electrolyte shifts.
Seek prompt medical attention for signs of severe dizziness, hearing changes, irregular heartbeat, or significant decrease in urination.
Bumetanide is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.